Perma-Fix Environmental Services Appoints Larry M. Shelton Chairman of the Board

ATLANTA, GA--(Marketwired - December 19, 2014) - Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) today announced that Larry M. Shelton, current member of the Board of Directors since 2006, has been appointed Chairman of the Board, replacing Dr. Lou Centofanti who will continue in his current role as President and CEO of the Company, as well as a member of the Board of Directors.

As an independent director at Perma-Fix Environmental Services, Mr. Shelton serves and will continue to serve on the Audit Committee, Strategic Advisory Committee and is Chairman of the Compensation and Stock Option Committee. In April 2014, he was appointed to the Board of Directors of Perma-Fix Medical S.A., a Polish subsidiary of the company involved in the development and manufacturing of medical isotopes. Since 1999, Mr. Shelton has been CFO of S.K. Hart Management, a private investment management company with interests in marketable securities, real estate and operating companies engaged in energy, agriculture and various other activities. He has over 18 years of experience as an executive financial officer for several waste management companies. Prior to S.K. Hart, Mr. Shelton was CFO of EnviroCare of Utah, Inc., a company focused on environmental issues, including remediation, emergency response and waste management. His previous experience also includes CFO of USPCI, Inc., a New York Stock Exchange listed company, and a number of board appointments, including Subsurface Technologies, Inc., a privately-held company specializing in providing environmentally sound innovative solutions for water well rehabilitation and development.

Dr. Lou Centofanti, Chief Executive Officer, commented, "Larry has been a valuable resource to Perma-Fix since joining the board in 2006. His knowledge base on the environmental side of the business and his financial expertise make him ideally suited to take on the role of Chairman of the Board. Given the turnaround in our core business as well as the traction we are gaining within our medical isotope business, separating the roles of CEO and Chairman will provide us additional resources to evaluate and pursue various growth opportunities. At the same time, given his role as an independent board member, separation of the roles of Chairman and CEO further reinforces our commitment to good corporate governance."